Fabry Disesase clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • HM15421/GC1134A in Patients With Fabry Disease

    open to eligible people ages 18 years and up

    This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.

    Los Angeles, California and other locations

Our lead scientists for Fabry Disesase research studies include .

Last updated: